Innovent Biologics' Groundbreaking Phase 3 Study of Mazdutide in Chinese Adults Published in NEJM, Marks Milestone in Obesity Treatment

Reuters

05-26

Innovent Biologics' Groundbreaking Phase 3 Study of Mazdutide in Chinese Adults Published in NEJM, Marks Milestone in Obesity Treatment

SUZHOU, China, May 25, 2025 -- Innovent Biologics, Inc., a leading biopharmaceutical company, has announced the publication of the results from a Phase 3 clinical study of mazdutide, a dual glucagon $(GCG.UK)$ and glucagon-like peptide-1 (GLP-1) receptor agonist, in The New England Journal of Medicine. The study, GLORY-1, focused on Chinese adults with overweight or obesity and marks a significant advancement in the field of metabolic and endocrine therapies developed in China. This study provides robust clinical evidence for the treatment of overweight and obesity, and it is the first clinical trial of its kind to be published in this prestigious medical journal. Innovent, through strategic collaborations and advanced research, continues to contribute to the goal of 'Healthy China 2030' by promoting science-based weight management solutions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN95667) on May 26, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2538808141"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2538808141\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2538808141?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-26 08:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2538808141","market":"nz","top_or_hot":-1,"title":"Innovent Biologics' Groundbreaking Phase 3 Study of Mazdutide in Chinese Adults Published in NEJM, Marks Milestone in Obesity Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Innovent Biologics' Groundbreaking Phase 3 Study of Mazdutide in Chinese Adults Published in NEJM, Marks Milestone in Obesity Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        SUZHOU, China, May 25, 2025 -- Innovent Biologics, Inc., a leading biopharmaceutical company, has announced the publication of the results from a Phase 3 clinical study of mazdutide, a dual glucagon <a href=\"https://laohu8.com/S/GCG.UK\">$(GCG.UK)$</a> and glucagon-like peptide-1 (GLP-1) receptor agonist, in The New England Journal of Medicine. The study, GLORY-1, focused on Chinese adults with overweight or obesity and marks a significant advancement in the field of metabolic and endocrine therapies developed in China. This study provides robust clinical evidence for the treatment of overweight and obesity, and it is the first clinical trial of its kind to be published in this prestigious medical journal. Innovent, through strategic collaborations and advanced research, continues to contribute to the goal of 'Healthy China 2030' by promoting science-based weight management solutions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN95667) on May 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innovent Biologics' Groundbreaking Phase 3 Study of Mazdutide in Chinese Adults Published in NEJM, Marks Milestone in Obesity Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnovent Biologics' Groundbreaking Phase 3 Study of Mazdutide in Chinese Adults Published in NEJM, Marks Milestone in Obesity Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-26 08:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Innovent Biologics' Groundbreaking Phase 3 Study of Mazdutide in Chinese Adults Published in NEJM, Marks Milestone in Obesity Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        SUZHOU, China, May 25, 2025 -- Innovent Biologics, Inc., a leading biopharmaceutical company, has announced the publication of the results from a Phase 3 clinical study of mazdutide, a dual glucagon <a href=\"https://laohu8.com/S/GCG.UK\">$(GCG.UK)$</a> and glucagon-like peptide-1 (GLP-1) receptor agonist, in The New England Journal of Medicine. The study, GLORY-1, focused on Chinese adults with overweight or obesity and marks a significant advancement in the field of metabolic and endocrine therapies developed in China. This study provides robust clinical evidence for the treatment of overweight and obesity, and it is the first clinical trial of its kind to be published in this prestigious medical journal. Innovent, through strategic collaborations and advanced research, continues to contribute to the goal of 'Healthy China 2030' by promoting science-based weight management solutions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN95667) on May 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1147","symbol_name":"投资银行业与经纪业","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250526:nNDL3LGflG:1","article_id":"2538808141","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2538808141","pubTimestamp":1748217619,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Innovent Biologics' Groundbreaking Phase 3 Study of Mazdutide in Chinese Adults Published in NEJM, Marks Milestone in Obesity Treatment. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire  on May 26, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1147":"投资银行业与经纪业","BK1161":"生物科技","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK1583":"高瓴概念","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","01801":"信达生物","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","01911":"华兴资本控股","BK1589":"北水核心资产"},"translate_title":"信达生物Mazdutide在中国成人中突破性3期研究发表于NEJM，标志着肥胖治疗的里程碑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":0.9,"01911":0.9},"content_text":"Innovent Biologics' Groundbreaking Phase 3 Study of Mazdutide in Chinese Adults Published in NEJM, Marks Milestone in Obesity Treatment\n    \n\n        SUZHOU, China, May 25, 2025 -- Innovent Biologics, Inc., a leading biopharmaceutical company, has announced the publication of the results from a Phase 3 clinical study of mazdutide, a dual glucagon $(GCG.UK)$ and glucagon-like peptide-1 (GLP-1) receptor agonist, in The New England Journal of Medicine. The study, GLORY-1, focused on Chinese adults with overweight or obesity and marks a significant advancement in the field of metabolic and endocrine therapies developed in China. This study provides robust clinical evidence for the treatment of overweight and obesity, and it is the first clinical trial of its kind to be published in this prestigious medical journal. Innovent, through strategic collaborations and advanced research, continues to contribute to the goal of 'Healthy China 2030' by promoting science-based weight management solutions.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN95667) on May 26, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}